Lipaglyn®

  • Zydus Discovery
  • Cardiology
www.lipaglyn.com

Lipaglyn is a novel drug used in the treatment of Diabetic Dyslipidemia. It is the first “Glitazar“ brand to receive approval and is the first New Chemical Entity (NCE) discovered and developed indigenously by an Indian Pharmaceutical Company. Lipaglyn is approved by the Drug Controller General Of India (DCGI). It has a dual mode of action on PPAR α and PPAR γ receptors, offers lipid and glucose-lowering effects in one molecule.

Brand Composition

  • Saroglitazar

 

Read More

Lipaglyn should be sold by retail to patients with a prescription from the registered healthcare practitioner only. It should be stored below 25℃ , in a dark place, and protected from direct sunlight.

Lipaglyn® Usage

The brand is used in the treatment of Diabetic Dyslipidemia.

Lipaglyn received the Online Media Innovation Golden Category Award at ACEF Global Customer Engagement in 2020.

Discovery-removebg-preview (2)

Lipaglyn received the Pharma Leaders Innovative Power Brand of the Year 2019 Award.

Pharma-Leader-Innovative-Power-Brand-Lipaglyn
SEE ALL BRANDS AT ZYDUS HEALTHCARE LIMITED